Today
Periodicals
Show Hide Related Items >> <<
09:19 Today Pfizer, Merck KGaA announce EC approval of Bavencio for UC patients 01/22/21 Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine 01/22/21 Coty promotes Stephane Delbos to chief procurement officer 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 08:37 Today Pfizer to ship fewer vaccine vials to fulfill commitment to U.S., NY Times says 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 12:18 Today Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 12:05 Today Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th
Hot Stocks
Show Hide Related Items >> <<
01/22/21 Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/08/21 Pfizer, BioNTech COVID vaccine elicits antibodies that neutralize mutation 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 12/29/20 Citi Arcturus selloff brings 'very good' buying opportunity, says Citi 12/22/20 Roth Capital Translate Bio price target raised to $37 from $30 at Roth Capital 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' 08/11/20 BioNTech reports Q2 EPS (EUR38c), consensus (EUR24c) 07/31/20 Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate
On The Fly
Show Hide Related Items >> <<
12:00 Today ReneSola falls -21.8% 10:00 Today ReneSola falls -21.1% 09:47 Today ReneSola falls -20.1% 01/12/21 ReneSola rises 12.4% 09:19 Today Pfizer, Merck KGaA announce EC approval of Bavencio for UC patients 01/22/21 Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine 01/22/21 Coty promotes Stephane Delbos to chief procurement officer 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 08:26 Today NCR Corp. to acquire Cardtronics for $39.00 per share in cash, sees accretion 01/24/21 Fly Intel: Top five weekend stock stories 01/21/21 Greenlight discloses new positions in Resideo and NCR, discusses FuboTV stake 01/11/21 NCR Corp. confirms offer to acquire Cardtronics for $39.00 per share in cash $142.70 / +11.65 (+8.89%)
08:32 Today Moderna announces results from COVID-19 Vaccine study against new strains 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 01/19/21 Moderna says cooperating with CDPH in probe of reports of adverse vaccine events 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 06:48 Today Merck ends work on COVID-19 vaccines, still working on therapeutic candidates 06:46 Today Merck discontinues development of COVID-19 vaccine candidates 01/20/21 Merck granted FDA approval of Verquvo for cardiosvacular risk reduction 01/19/21 Cocrystal Pharma completes research obligations under Merck agreement 11/17/20 Magnite sees total connected TV revenue up over 50% in Q3 09/29/20 Magnite announces expanded relationship with Discovery for advertising 09/22/20 Magnite names Katie Evans as COO 09/01/20 Ad tech firms Trade Desk, Cardlytics up after AT&T ponders sale of Xandr $95.00 / +30.27 (+46.76%)
12:00 Today GameStop rises 60.3% 11:15 Today GameStop halted again for volatility with shares well off highs at $88.09 10:53 Today GameStop halted for volatility after rising 104% to $132.32 10:42 Today GameStop is 'Blockbuster all over again," Loop Capital analyst says 08:45 Today Cardtronics trading resumes 08:21 Today Cardtronics trading halted, news pending 01/19/21 Bed Bath & Beyond completes sale of Cost Plus World Market to Kingswood 01/07/21 Bed Bath & Beyond drops 11% to $18.61 after Q3 results, guidance miss estimates 01/07/21 Bed Bath & Beyond: Guidance assumes flat comparable sales in FY21 01/07/21 Bed Bath & Beyond: Digital comp sales up 94% in Q3, store comp sales down 14% 12:00 Today BlackBerry rises 34.4% 11:12 Today BlackBerry 'not aware' of any material, undisclosed corporate developments 09:47 Today BlackBerry rises 39.8% 01/21/21 BlackBerry CFO Steve Rai sells almost $430K in company shares 07:11 Today Palihapitiya participating in deal between Spartan Acquisition II, Sunlight 07:10 Today Sunlight Financial to become public through $1.3B Spartan Acquisition merger 01/04/21 Takkion Holdings acquires Renew Energy; terms not disclosed 01/21/21 Wedbush Scholar Rock price target raised to $66 from $47 at Wedbush 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair 01/20/21 Citi Citi opens 'negative Catalyst Watch' on Bristol-Myers 01/06/21 Citi Citi opens 'positive catalyst watch' on Merck $95.00 / +30.27 (+46.76%)
09:52 Today Fly Intel: Top five analyst downgrades 08:57 Today Telsey Advisory GameStop continues surge despite double downgrade at Telsey Advisory 05:37 Today Telsey Advisory GameStop downgraded to Underperform from Outperform at Telsey Advisory 01/13/21 Standpoint Research GameStop downgraded to Hold from Buy at Standpoint Research $142.70 / +11.65 (+8.89%)
09:47 Today Piper Sandler Piper reiterates $170 target on Moderna with vaccine active on new strains 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/06/21 Piper Sandler Moderna price target raised to $170 after EU vaccine approval at Piper Sandler 01/04/21 Piper Sandler Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/11/21 Wells Fargo Wells Fargo not ruling out counter-bid for Cardtronics slightly higher than $39 01/11/21 JPMorgan NCR bid for Cardtronics makes sense, says JPMorgan 01/11/21 Stephens NCR Corp. price target raised to $49 from $39 at Stephens 12/14/20 Craig-Hallum Par Technology price target raised to $75 from $55 at Craig-Hallum 11:00 Today Truist Cardtronics downgraded to Hold from Buy at Truist 01/20/21 Truist Athene Holding price target raised to $55 from $48 at Truist 01/11/21 Wells Fargo Apollo Global price target raised to $55 from $50 at Wells Fargo 12/18/20 Deutsche Bank Apollo Global price target raised to $51 from $49 at Deutsche Bank 11/06/20 Fly Intel: Top five analyst upgrades 07:22 Today Loop Capital Bed Bath & Beyond price target raised to $30 from $18 at Loop Capital 01/08/21 Wedbush Bed Bath & Beyond Q3 results 'mixed,' says Wedbush 01/08/21 Baird Bed Bath & Beyond elevated to Fresh Pick at Baird 01/05/21 Baird Bed Bath & Beyond Q3 expectations remain low, says Baird 12/18/20 TD Securities BlackBerry price target raised to $8.50 from $5.50 at TD Securities 12/15/20 RBC Capital BlackBerry price target raised to $7.50 from $5 at RBC Capital 12/15/20 RBC Capital BlackBerry price target raised to $7.50 from $5.00 at RBC Capital 12/01/20 TD Securities BlackBerry jump on AWS pact looks like overreaction, says TD Securities 12/15/20 Roth Capital Solar tax credit extension would be positive surprise, says Roth Capital 12/14/20 H.C. Wainwright ReneSola price target raised to $12 from $4 at H.C. Wainwright 09/17/20 H.C. Wainwright ReneSola initiated with a Buy at H.C. Wainwright 03/03/20 LD Micro to hold a virtual conference 01/24/21 Truist Magnite downgraded to Hold from Buy at Truist 01/22/21 Craig-Hallum Magnite price target raised to $45 from $25 at Craig-Hallum 01/11/21 Susquehanna Magnite weakness a buying opportunity, says Susquehanna 12/21/20 Needham Magnite price target raised to $30 from $18 at Needham 12/01/20 ReneSola sees Q4 revenue $23M-$25M, consensus $33.31M 12/01/20 ReneSola reports Q3 non-GAAP EPS 5c, consensus 0c 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 10/27/20 NCR Corp. reports Q3 EPS 54c, consensus 39c 07/28/20 NCR Corp. says 2020 outlook remains withdrawn 07/28/20 NCR Corp. reports Q2 EPS 27c, consensus 21c $142.70 / +11.65 (+8.89%)
10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 08/05/20 Moderna reports Q2 EPS (31c), consensus (35c) 10/27/20 Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78 10/27/20 Merck reports Q3 adjusted EPS $1.74, consensus $1.43 10/26/20 Notable companies reporting before tomorrow's open 11/09/20 Magnite sees Q4 revenue $72M-$75M, consensus $66.81M 11/09/20 Magnite reports Q3 EPS 6c, consensus (4c) 08/10/20 Magnite reports Q2 EPS (10c), consensus (14c) $95.00 / +30.27 (+46.76%)
12/08/20 GameStop reports Q3 adj. EPS (53c), consensus (85c) 12/08/20 GameStop reports Q3 EPS (29c), consensus (85c) 12/08/20 Notable companies reporting after market close 09/09/20 GameStop reports Q2 adj. EPS ($1.40), consensus ($1.13) 10/29/20 Cardtronics reports Q3 adj. EPS 49c, consensus 34c 08/06/20 Cardtronics reports Q2 EPS 13c, consensus (6c) 01/07/21 Bed Bath & Beyond sees FY21 revenue $8B-$8.2B, consensus $9.61B 01/07/21 Bed Bath & Beyond sees Q4 revenue down double-digit percent, consensus $2.92B 01/07/21 Bed Bath & Beyond reports Q3 adjusted EPS 8c, consensus 19c 01/06/21 Notable companies reporting before tomorrow's open 12/17/20 BlackBerry reports Q3 adjusted EPS 2c, consensus (1c) 09/24/20 BlackBerry reports Q2 non-GAAP EPS 11c, consensus 2c 10/29/20 Apollo Global reports Q3 fee-related EPS 63c, consensus 49c 07/30/20 Apollo Global reports Q2 fee-related EPS 59c, consensus 48c
Options
Show Hide Related Items >> <<
09:19 Today Pfizer, Merck KGaA announce EC approval of Bavencio for UC patients 01/22/21 Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine 01/22/21 Coty promotes Stephane Delbos to chief procurement officer 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 08:37 Today Pfizer to ship fewer vaccine vials to fulfill commitment to U.S., NY Times says 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th
Hot Stocks
Earlier, EMD Serono, the…
Earlier, EMD Serono, the Healthcare business sector of Merck KGaA (MKGAY) and Pfizer (PFE) announced that the European Commission has approved Bavencio as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma, or UC, who are progression-free following platinum-based chemotherapy. Bavencio was first approved in the U.S. as a first-line maintenance treatment for advanced UC by the U.S. Food and Drug Administration in June 2020 and is now approved for this indication in 38 countries, the companies said. Additional regulatory applications are under review in 13 countries, including in Japan, where approval is expected in H1 2021.
Show Hide Related Items >> <<
01/22/21 Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine 01/22/21 Coty promotes Stephane Delbos to chief procurement officer 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/20/21 Merck KGaA discontinues clinical trial for bintrafusp alfa in lung cancer 12/11/20 Pfizer, EMD Serono: BAVENCIO receives positive CHMP opinion 10/09/20 Precigen: Merck KGaA increases ownership stake by exercising convertible note 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/04/21 JPMorgan Merck KGaA upgraded to Overweight from Neutral at JPMorgan 11/20/20 Pareto Merck KGaA upgraded to Buy from Hold at Pareto 11/16/20 AlphaValue Merck KGaA upgraded to Add from Reduce at AlphaValue 10/13/20 Barclays Merck KGaA upgraded to Equal Weight from Underweight at Barclays 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 08:37 Today Pfizer to ship fewer vaccine vials to fulfill commitment to U.S., NY Times says 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says 08/10/20 Thermo Fisher tender for Qiagen may fail, other suitors could step in, CTFN says 08/10/20 Qiagen may have other suitors if Thermo bid fails, CTFN says 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th
Friday
Hot Stocks
Pfizer (PFE) and BioNTech…
Pfizer (PFE) and BioNTech (BNTX) announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021. COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment financial mechanism that aims to ensure that 92 low- and lower-middle-income countries will be able to secure access to COVID-19 vaccines at the same time as higher-income countries. The first doses are expected to be delivered in the first quarter of 2021, subject to the negotiation and execution of supply agreements under the COVAX Facility structure. For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price. Financial terms of the agreement were not disclosed.
Show Hide Related Items >> <<
01/22/21 Coty promotes Stephane Delbos to chief procurement officer 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/08/21 Pfizer, BioNTech COVID vaccine elicits antibodies that neutralize mutation 01/07/21 BioNTech reports publication of preclinical data on novel mRNA vaccine approach 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 12/29/20 Citi Arcturus selloff brings 'very good' buying opportunity, says Citi 12/22/20 Roth Capital Translate Bio price target raised to $37 from $30 at Roth Capital 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 08/11/20 BioNTech reports Q2 EPS (EUR38c), consensus (EUR24c) 07/31/20 Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate
Hot Stocks
Coty (COTY) announced the…
Coty (COTY) announced the promotion of Stephane Delbos to chief procurement officer, or CPO, effective February 1. Delbos, who joined Coty in 2010 as global sourcing director, has been promoted from his current role as senior VP for transformation, indirect and procurement operations, where he has played an important role in driving forward Coty's broader transformation agenda. Delbos will join Coty's senior leadership team and report to Gordon von Bretten, chief transformation officer. Delbos is a senior procurement professional with over 18 years' experience in the beauty and pharmaceutical industries. Prior to joining Coty, he held several local and global procurement positions at Pfizer (PFE). In his new role, Delbos will be responsible for implementing Coty's multi-year procurement strategy, which includes achieving a significant cost reduction target by FY23, reducing complexity and strengthening Coty's new product pipeline. This forms an important element of Coty's transformation program, announced in 2020.
Show Hide Related Items >> <<
01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 12/09/20 Coty CFO Pierre-Andre Terisse to switch roles, Laurent Mercier to succeed 11/27/20 Coty falls -8.5% 11/19/20 Coty rises 13.5% 11/06/20 Coty rises 23.0% 12/07/20 Wells Fargo Coty downgraded to Underweight from Equal Weight at Wells Fargo 11/19/20 Fly Intel: Top five analyst upgrades 11/19/20 Citi Coty upgraded to Buy from Neutral at Citi 11/09/20 Deutsche Bank Coty price target raised to $6 from $4 at Deutsche Bank 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 11/06/20 Coty reports Q1 adjusted EPS 11c, consensus (5c) 08/27/20 Coty reports Q4 adjusted cont ops EPS (46c), consensus (11c) 08/27/20 Coty reports Q4 adjusted EPS (51c), consensus (11c) 08/26/20 Notable companies reporting before tomorrow's open 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 11/30/20 Fly Insider: Merrimack, Catalent among weeks notable insider trades 10/07/20 Fly Intel: After-Hours Movers 10/07/20 JetBlue double upgrade among today's top calls on Wall Street 10/07/20 Fly Intel: Pre-market Movers 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th 12/22/20 Coty call volume above normal and directionally bullish 11/30/20 Coty call volume above normal and directionally bullish 11/25/20 Unusually active option classes on open November 25th 11/19/20 Coty call volume above normal and directionally bullish
Thursday
Hot Stocks
ViiV Healthcare, the…
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.
Show Hide Related Items >> <<
01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 01/21/21 Addex Therapeutics receives IND approval to start study in epilepsy 01/19/21 Royalty Pharma acquires royalty interest in Seltorexant from Minerva 01/19/21 Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M 01/15/21 Halozyme says Janssen receives FDA approval of Darzalex Faspro 01/21/21 BiondVax names Amir Reichman as new CEO 01/12/21 Vir Biotechnology, GlaxoSmithKline to evaluate VIR-7832 in COVID-19 patients 01/11/21 Eligo Bioscience enters research, option agreement with GlaxoSmithKline 12/21/20 Ligand, GSK in pact 'leveraging' Icagen's small molecule 'expertise' 01/20/21 UBS GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS 01/20/21 Fly Intel: Top five analyst downgrades 01/20/21 Credit Suisse GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse 01/20/21 Credit Suisse GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/15/21 B. Riley Securities Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities 12/29/20 Piper Sandler Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 10/13/20 Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021 10/13/20 Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B 10/13/20 Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95 10/13/20 Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports 01/13/21 Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says 01/13/21 J&J chief science officer sees possible vaccine approval by March, Reuters says 01/13/21 J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says 01/13/21 EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports 01/12/21 GSK looks to double blockbusters in portfolio by 2026, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 12/11/20 GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 01/14/21 Fly Intel: Wall Street's top stories for Thursday 01/14/21 Fly Intel: Wall Street's top stories at midday 01/13/21 Fly Intel: Wall Street's top stories for Wednesday 12/29/20 Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th 09/23/20 Unusually active option classes on open September 23rd 08/24/20 Unusually active option classes on open August 24th 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st
Periodicals
Pfizer (PFE) has cut in…
Pfizer (PFE) has cut in half the volume of COVID-19 vaccines it will deliver to some EU countries this week, Reuters' Radu-Sorin Marinas, Jan Lopatka, and Tsvetelia Tsolova report, citing government officials. Pfizer and its partner BioNTech (BNTX) have declined to comment on the cuts beyond their statement last week, the report noted. Reference Link
Show Hide Related Items >> <<
01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/08/21 Pfizer, BioNTech COVID vaccine elicits antibodies that neutralize mutation 01/07/21 BioNTech reports publication of preclinical data on novel mRNA vaccine approach 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 12/29/20 Citi Arcturus selloff brings 'very good' buying opportunity, says Citi 12/22/20 Roth Capital Translate Bio price target raised to $37 from $30 at Roth Capital 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 08/11/20 BioNTech reports Q2 EPS (EUR38c), consensus (EUR24c) 07/31/20 Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate